MPS Pharmaa Limited (Formerly Advik Laboratories) FY26 Financial Update

MPS Pharmaa Limited reported a net loss of ₹1.02 crore for the financial year ended March 31, 2026. The company's revenue from operations was ₹0 crore.

Reader Takeaway: Widening losses and audit concerns overshadow speculative plans to restart operations, signaling high risk.

What just happened

MPS Pharmaa Limited, formerly Advik Laboratories Limited, has declared a net loss of ₹1.02 crore for the fiscal year ending March 31, 2026. This is an increase from the ₹0.8979 crore loss recorded in the previous fiscal year. The company reported zero revenue from its core operations. Its total income stood at ₹3.56 lakh, a decrease of 25.37% from the prior year.

Why this matters

The widening net loss, absence of operational revenue, and a modified audit opinion raise significant concerns for investors. These factors, coupled with a trading suspension on the BSE, indicate severe financial and operational challenges for the company.

The backstory

The company has been non-operational for a considerable period, relying on 'Other Income' rather than core business activities. Management has indicated plans to apply for license renewals and seek prospective buyers to restart operations, but these are speculative at this stage.

What changes now

With a significant net loss and auditor's qualified opinion, the company's financial health is under severe strain. The trading suspension on the BSE, due to non-payment of annual listing fees, further limits liquidity and investor access to the stock. The company also relies on loans from related parties.

Risks to watch

Key risks include the lack of verifiable operational revenue, the auditor's inability to confirm the existence and fair value of investments totaling ₹0.538 crore, and the status of stalled capital projects worth ₹2.41 crore. The company's future hinges on speculative plans to restart business and resolve compliance issues.

Peer comparison

As MPS Pharmaa Limited is largely non-operational with suspended trading, a direct financial or operational peer comparison is not currently meaningful. Its situation is distinct due to the lack of core business activity and significant governance concerns.

Context metrics (time-bound)

• Financial Year: Ended March 31, 2026
• Net Loss: ₹1.02 crore (₹102.00 lakh)
• Revenue from Operations: ₹0 crore
• Total Income: ₹0.0356 crore (₹3.56 lakh)
• Investment Value (Unverified): ₹0.538 crore (₹53.80 lakh)
• Stalled Capital Projects: ₹2.41 crore (₹241 lakh)
• Related Party Loans (Ontam Global Capital): ₹6.6378 crore (₹663.78 lakh)

What to track next

Investors should closely monitor any concrete progress on license renewals, potential buyer engagements, and resolution of the auditor's concerns regarding investments and stalled projects. The lifting of the BSE trading suspension will also be a key event to track.